1174395-19-7

Brodalumab has been used in trials studying the treatment of Asthma, Psoriasis, Crohn's Disease, Psoriatic Arthritis, and Rheumatoid Arthritis. Brodalumab was FDA approved in February, 2017 as Siliq for the treatment of moderate-to-severe plaque psoriasis.

Human monoclonal immunoglobulin IgG2 antibody:

Treatment of moderate to severe plaque psoriasis

Potentially hazardous interactions with other drugs
Avoid with live vaccines.

Brodalumab is expected to be degraded into small peptides and amino acids via catabolic pathways in a manner similar to endogenous IgG. Brodalumab is expected to be mainly eliminated via catabolism and hepatic impairment is not expected to influence clearance.